Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (7704)	11/10/1998 7:21:00 PM
From: Robert S.	Read Replies (1) \| Respond to of 17367

No, no, no, Tharos, you are missing the point. As I have stated previously, I believe BPI does show promise in combating this malady. Ignoring potential pitfalls, however, that may arise in the utilization of rBPI21 as a therapeutic treatment, will not make them disappear. Endotoxins may be only part of the picture as the excerpt below (Natanson, et al.) from my previous post illustrates: Targeting a single microbial toxin such as endotoxin may not represent a viable strategy for treating a complex inflammatory response to diverse gram-negative bacteria. Similarly, the strategy of inhibiting the host inflammatory response may not be beneficial because immune cells and cytokines play both pathogenic and protective roles. Finally, our scientific knowledge of the complex timing of mediator release and balance during sepsis may be insufficient to develop successful therapeutic interventions for this syndrome.